Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity

• Main Authors: Si-Yu Yuan (Author), Hai-Bo Yu (Author), Zhen Yang (Author), Yi-Ping Qin (Author), Ji-Hua Ren (Author), Sheng-Tao Cheng (Author), Fang Ren (Author), Betty Yuen Kwan Law (Author), Vincent Kam Wai Wong (Author), Jerome P. L. Ng (Author), Yu-Jiao Zhou (Author), Xin He (Author), Ming Tan (Author), Zhen-Zhen Zhang (Author), Juan Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Current anti-HBV therapeutic strategy relies on interferon and nucleos(t)ide-type drugs with the limitation of functional cure, inducing hepatitis B surface antigen (HBsAg) loss in very few patients. Notably, the level of HBsAg has been established as an accurate indicator to evaluate the drug effic...